809 Exploring the therapeutic benefit of AVA-NP-695 (ENPP1 inhibitor) and DNA damage inhibition to activation of the immune system in metastatic osteosarcoma
Year: 2024
Type: conference-abstract
Abstract: Background The osteosarcoma (OS) genome is characterized by high chromosomal instability (CIN). CIN is a hallmark of many human cancers, and it is associated with metastasis, immune evasion, and therapeutic resistance. CIN leads to Micronuclei (MN) formation and cytosolic dsDNA, resulting in activation of the cGAS-STING pathway. Given high levels of CIN in human cancers, it is not surprising that this anti-tumoral axis is paradoxically co-opted to provide immune evasion rather than immune surveillance. Some CIN-high cancers switch from IFN to NF-κβ ‘non-canonical’ STING-mediated signaling. CINhigh tumors can also induce the expression of ENPP1 to hydrolyze cGAMP, which dampens the downstream effects of cGAMP on immune cell activation. Methods The inhibition potency of AVA-NP-695 was confirmed by enzymatic assays using substrates p-Nitrophenyl-5′-TMP and 2′3′-cGAMP. Pharmacokinetic profile of AVA-NP-695 in Mice, Rats and Beagle Dogs and the human PK profile was predicted. The efficacy of AVA-NP-695 was demonstrated in F420- C57/BL6 mice and K7M2-BALB/c mice as monotherapy and in combination with clinically approved DDR-inhibitors like Olaparib. Results RNAseq data revealed that the highest ENPP1 expression levels were found in Ewing sarcoma, Osteosarcoma (OS) and breast cancer. We evaluated ENPP1 expression, cGAMP export after stimulation with dsDNA and ENPP1 activity using a biochemical assay in a panel of OS cell lines, including OSPDX-cell lines. ENPP1 activity varied significantly, with OS384 and OS526 having the highest. We tested AVA-NP-695, a selective and potent small molecule ENPP1 inhibitor, orally bioavailable and cell permeable which exhibited no adverse effects in repeat dose and dose escalation toxicity studies in mice and beagle dogs. Moreover, compassionate use of AVA-NP-695 showed > 80% tumor volume reduction in Canine patients. AVA-NP-695 restored cGAMP levels and observed a significant increase in cGAMP levels (~2–3 fold) as early as 6 hours after treatment. Results from a targeted pharmacological screen uncovered an unexpectedly synthetic lethality with Olaparib (PARPi) in combination with AVA-NP-695 in vitro. This novel combination increased both intra- and extracellular cGAMP production in vitro, led to OS tumor regression and boosts antitumor immune responses in both OT and metastatic context. Conclusions The anti-tumor efficacy of AVA-NP-695 in monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 in pediatrics tumors like Osteosarcoma. Our results uncover novel mechanistic vulnerabilities and suggest that treatment with AVA-NP-695 in combination may increase effectiveness in patients, thus preventing local and distant dissemination.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W4404064483
